Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 43 Carcinoma, Hepatocellular 41 Carcinoma, Non-Small-Cell Lung 17 Colorectal Neoplasms 14 Breast Neoplasms 14 Small Cell Lung Carcinoma 12 Sarcoma 11 Ovarian Neoplasms 11 Nasopharyngeal Carcinoma 11 Triple Negative Breast Neoplasms 10 Lung Neoplasms 10 Cholangiocarcinoma 10 Esophageal Squamous Cell Carcinoma 9 Esophageal Neoplasms 9 Osteosarcoma 8 Biliary Tract Neoplasms 8 Advanced Gastric Cancer 8 Neoplasms 6 Head and Neck Neoplasms 6 Uterine Cervical Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Recurrence 5 Pancreatic Neoplasms 5 Neoplasm Metastasis 5 Liver Neoplasms 5 Glioma 5 Drug-Related Side Effects and Adverse Reactions 4 Thyroid Neoplasms 3 Melanoma 3 Gastrointestinal Neoplasms 3

Interventions

Surveys and Questionnaires 7 Standard of Care 5 Sirolimus 5 Bevacizumab 5 temsirolimus 4 Interviews as Topic 4 Paclitaxel 3 olaparib 2 Vorinostat 2 Olanzapine 2 Magnetic Resonance Spectroscopy 2 Gemcitabine 2 Everolimus 2 Erlotinib Hydrochloride 2 Dasatinib 2 Cetuximab 2 zaleplon 1 vistusertib 1 tilsotolimod 1 pazopanib 1 olanzapine-fluoxetine combination 1 nimotuzumab 1 liposomal doxorubicin 1 capivasertib 1 apatinib 1 Videotape Recording 1 Vemurafenib 1 Valproic Acid 1 Trastuzumab 1 Topotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Cancer × apatinib × Clear all

NCT03645200 2019-04-25

Treatment of Carrying TP53 Harmful Mutations

Tianjin Medical University Second Hospital

Phase 1 Unknown

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡